AKIN GUMP STRAUSS HAUER & FELD

Lobbying for UCB, INC. · Biopharmaceutical company

Filing 2nd Quarter - Report

2nd Quarter (Apr 1 - June 30) 2026 · Georgia · House · Senate · $80,000.00 income · posted Jul 20, 2026

Lobbying activity 1

Trade (domestic/foreign)

Issues related to global biopharmaceutical supply chains; Issues related to Section 232 investigations on pharmaceuticals.

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.